Search

Your search keyword '"Carraway, Hetty E."' showing total 1,147 results

Search Constraints

Start Over You searched for: Author "Carraway, Hetty E." Remove constraint Author: "Carraway, Hetty E."
1,147 results on '"Carraway, Hetty E."'

Search Results

2. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

7. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

8. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

9. Molecular patterns identify distinct subclasses of myeloid neoplasia

11. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

12. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

13. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

14. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

15. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

17. Mutation profiles and outcomes of patients with acute myeloid leukemia with autoimmune disease.

18. Covalent-103: A phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL).

19. Outcomes of blast-phase MPN and JAK2, MPL, and CALRmutated de novo AML: A propensity score-adjusted cohort study.

20. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

21. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

22. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia

27. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

28. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

29. Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia

30. Leukemia evolving from paroxysmal nocturnal hemoglobinuria

33. POSTER: AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)

34. AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)

35. Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature

38. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

40. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia

41. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)

42. An Agenda to Advance Research in Myelodysplastic Syndromes: A TOP 10 Priority List From the First International Workshop in MDS

44. Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

46. Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation

47. Supplemental Data from A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

48. Supplements from IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

49. Supplemental Figures and Tables from A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

50. Data from Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies

Catalog

Books, media, physical & digital resources